Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.16 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $9.25 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• Amrize Ltd (AMRZ) PT Lowered to $42 at UBS on Lower Earnings Estimates
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue